Skip to Content
Merck
CN
All Photos(1)

Documents

MAB2052

Sigma-Aldrich

Anti-Disialoganglioside GD2 Antibody, clone 14G2a

clone 14.2Ga, Chemicon®, from mouse

Sign Into View Organizational & Contract Pricing

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

clone

14.2Ga, monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

flow cytometry: suitable
immunofluorescence: suitable
immunohistochemistry: suitable

isotype

IgG2a

shipped in

wet ice

target post-translational modification

unmodified

Related Categories

Specificity

Reacts specifically with human GD2 ganglioside.

Application

Anti-Disialoganglioside GD2 Antibody, clone 14G2a detects level of Disialoganglioside GD2 & has been published & validated for use in FC, IF, IH.
Immunohistochemistry (frozen tissue sections)(Cheresh et al., 1986)

Immunofluorescence of cells in culture

Flow cytometry: 1-2 μg per 10E6 cells

Cytotoxicity for GD2 positive cells (Mujoo et al., 1987, 1989)

Optimal working dilutions must be determined by end user.

Physical form

Cell culture supernatant in 0.02M PB, pH 7.6, 0.25M NaCl containing 0.1% Sodium Azide
Format: Purified

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hideki Yoshida et al.
Scientific reports, 10(1), 1199-1199 (2020-01-29)
β-1,4-N-Acetyl-Galactosaminyltransferase 1 (B4GALNT1) encodes the key enzyme B4GALNT1 to generate gangliosides GM2/GD2. GM2/GD2 gangliosides are surface glycolipids mainly found on brain neurons as well as peripheral nerves and skin melanocytes and are reported to exacerbate the malignant potential of melanomas.
Patrizia Garbati et al.
Biomedicines, 8(11) (2020-11-07)
To overcome the lack of effective pharmacological treatments for high-risk neuroblastoma (HR-NB), the development of novel in vitro and in vivo models that better recapitulate the disease is required. Here, we used an in vitro multiclonal cell model encompassing NB
Christian M Seitz et al.
Oncoimmunology, 9(1), 1683345-1683345 (2020-02-01)
Expression of the disialoganglioside GD2 has been identified as a marker antigen associated with a breast cancer stem-like cell (BCSC) phenotype. Here, we report on the evaluation of GD2 as a BCSC-specific target antigen for immunotherapy. GD2 expression was confirmed
Patrizia Garbati et al.
International journal of molecular sciences, 22(13) (2021-07-03)
High-risk neuroblastoma (HR-NB) still remains the most dangerous tumor in early childhood. For this reason, the identification of new therapeutic approaches is of fundamental importance. Recently, we combined the conventional pharmacological approach to NB, represented by cisplatin, with fendiline hydrochloride
Antonella Brizzolara et al.
Molecules (Basel, Switzerland), 25(22) (2020-11-14)
Despite significant improvement of neuroblastoma (NB) patients' survival due to recent treatment advancements in recent years, NB is still associated with high mortality rate. In search of novel strategies to increase NB's susceptibility to pharmacological treatments, we investigated the in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service